The worldwide pandemic of 2019 novel coronavirus disease (COVID-19) has posed the most substantial and severe public health issue for several generations, and therapeutic options have not yet been optimised. Vitamin D (in its “parent” form, cholecalciferol) has been proposed in the pharmacological management of COVID-19 by various sources. We aimed to determine whether COVID-19 mortality was affected by serum 25-hydroxyvitamin D (25(OH)D) levels, vitamin D status, or cholecalciferol therapy, and to elucidate any other predictors of COVID-19 mortality. Patients hospitalised with COVID-19 were opportunistically recruited from three UK hospitals, and their data were collected retrospectively. Logistic regression was used to determine any relationships between COVID-19 mortality and potential predictors, including 25(OH)D levels and cholecalciferol booster therapy. A total of 986 participants with COVID-19 were studied, of whom 151 (16.0%) received cholecalciferol booster therapy. In the primary cohort of 444 patients, cholecalciferol booster therapy was associated with a reduced risk of COVID-19 mortality, following adjustment for potential confounders (OR adj 0.13, 95% CI 0.05–0.35, p < 0.001). This finding was replicated in a validation cohort of 541 patients (OR adj 0.38, 95% CI 0.17–0.84, p = 0.018). In this observational study, treatment with cholecalciferol booster therapy, regardless of baseline serum 25(OH)D levels, appears to be associated with a reduced risk of mortality in acute in-patients admitted with COVID-19. Further work with large population studies needs to be carried out to determine adequate serum 25(OH)D levels, as well as multi-dose clinical trials of cholecalciferol therapy to assess maximum efficacy.
【저자키워드】 COVID-19, SARS-CoV-2, Mortality, Vitamin D, cholecalciferol, 25-hydroxyvitamin D, vitamin D treatment, novel coronavirus 2019, 【초록키워드】 Treatment, 2019 novel coronavirus disease, coronavirus disease, public health, Efficacy, clinical trial, Vitamin D, cholecalciferol, 25-hydroxyvitamin D, predictors, novel coronavirus disease, observational study, Novel coronavirus, 2019 novel coronavirus, serum, Cohort, Patient, Logistic regression, predictor, disease, patients, therapeutic options, Vitamin D status, COVID-19 mortality, therapeutic option, population studies, 95% CI, reduced risk, worldwide pandemic, pharmacological management, participant, cholecalciferol booster therapy, cholecalciferol therapy, validation cohort, serum 25-hydroxyvitamin D, UK hospitals, hospitalised, confounder, affected, was used, collected, carried, recruited, appear, determine, replicated, baseline, in-patient, with COVID-19, 【제목키워드】 cholecalciferol,